Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.
about
Perspectives on menopause and women with HIVRacial differences in bone loss and relation to menopause among HIV-infected and uninfected women.The protease inhibitors and HIV-associated bone loss.Tenofovir and bone health.Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patientsSecond European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, SpainThe ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirPharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.Bone Disease in HIV: Recommendations for Screening and Management in the Older Patient.Management of bone mineral density in HIV-infected patients.Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.Protecting bone in long-term HIV positive patients receiving antiretrovirals.Switching antiretroviral regimes for the treatment of HIV: safety implications.HIV and Bone Complications: Understudied Populations and New Management Strategies.Heel quantitative ultrasound in HIV-infected patients: a cross-sectional study.Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.Endocrinological aspects of HIV infection.Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.Ageing with HIV.Mexican patients with HIV have a high prevalence of vertebral fractures.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q26772852-20E4BC72-FC1E-4CCF-BE83-08ECAABFC28DQ35564782-02EABD7C-69CE-43AB-9638-80A58A0CCE07Q36818259-D17724EC-7B16-4865-BABA-176041BC9045Q36833961-73711EEF-E5FF-417E-B931-5315E6A5909AQ36931691-37AA6703-CB7C-4481-82C2-2C3A845D8697Q37098390-44C3FE1C-8A82-4CAD-9771-95A8216B3860Q37279429-A9B08A6E-7B6B-4659-84B4-CD5A6A8CAC0DQ38527537-51E4973B-E710-4F83-99F5-A87F366F9627Q38540406-3CEF414E-F6B9-4C75-ADE6-7BF742BBFF5BQ38711437-E0C6E3BB-D357-44BF-A903-911D0CFE5149Q38801873-74F6379A-E8EC-4728-A481-72884F9C2FBBQ38836871-888764FC-E0B5-44A7-AA03-29B8573A1B94Q38879406-D779ABA3-68F4-4806-B663-345979EBCD90Q38978479-9BA73DFF-51EF-4407-8919-FB86F501CF55Q39357708-CEEF2227-D6F7-457C-A281-9D774E40E374Q41432679-B074CFF3-B327-444A-BB93-7B5091934F93Q47219853-AD7AA32A-D611-4198-A62D-0E39D54178F7Q49564927-C5019581-C2FC-4498-B449-CE43DC3C8316Q50001938-3C5CCD0E-EFBF-4DFA-A32B-BF452FE9B368Q54222374-D5FBADAC-04DB-45BF-82CD-DE52242D8BB4Q57180790-D23110DF-68C6-4C13-A13F-1B86E441DE63
P2860
Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Switch from tenofovir to ralte ...... f bone turnover over 48 weeks.
@en
Switch from tenofovir to ralte ...... f bone turnover over 48 weeks.
@nl
type
label
Switch from tenofovir to ralte ...... f bone turnover over 48 weeks.
@en
Switch from tenofovir to ralte ...... f bone turnover over 48 weeks.
@nl
prefLabel
Switch from tenofovir to ralte ...... f bone turnover over 48 weeks.
@en
Switch from tenofovir to ralte ...... f bone turnover over 48 weeks.
@nl
P2093
P2860
P356
P1433
P1476
Switch from tenofovir to ralte ...... f bone turnover over 48 weeks.
@en
P2093
R Richardson
TROP (Switch from Tenofovir to Raltegravir for Low Bone Density) study team
P2860
P304
P356
10.1111/HIV.12123
P577
2014-01-26T00:00:00Z